NCT04498325撤回1 期
A Phase I and Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Safe and tolerable dose of NT-I7 (Phase I only)
研究概览
简要总结
Lymphopenia is common in patients with COVID-19 and is associated with worse clinical outcomes. NT-I7 is a long-acting human interleukin-7 (IL-7) that has been shown to increase absolute lymphocyte count (ALC) and CD4+ and CD8+ T cell counts with a well-tolerated safety profile in humans. In this study, patients who have tested positive for SARS-CoV-2 by PCR testing without severe disease and with ALC <1500 cells/mm3 will be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
The clinicians, participants, and clinical research coordinators will be blinded
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Tested PCR positive for SARS-CoV-2by nasopharyngeal swab, oropharyngeal swab, or saliva.
- •Mild COVID-19, defined as WHO Ordinal Scale <4 .
- •Respiratory rate < 20 bpm, HR < 90 bpm, and SpO2 > 93% on room air at sea level.
- •Absolute lymphocyte count (ALC) < 1500 cells/mm3 at the time of screening.
- •AST/ALT ≤ 3.0 x ULN, total bilirubin ≤ 1.5 x ULN (except if due to Gilbert's syndrome).
- •≥ 18 years of age.
- •First day of treatment must be no more than 10 days from onset of COVID-19 symptoms.
- •Must be willing to be closely monitored in the hospital or in an alternate setting (e.g. clinical trial unit) for at least the first 7 days (±2 days allowed) following NT-I7/placebo injection.
- •Individuals of reproductive potential must agree to either abstinence or use of at least one study-approved form of contraception when engaging in sexual activities that can result in pregnancy from the time of screening through 60 days for female and 120 days for male after study agent administration. Acceptable forms of contraception for this study are male or female condoms, diaphragms or cervical caps with a spermicide, or non-hormonal intrauterine devices.
- •Patients with factors or concomitant illness associated with higher risk of mortality due to COVID-19 (such as older age, hypertension, diabetes, and/or COPD) are eligible.
- •Able to understand and willing to sign an IRB approved written informed consent document.
排除标准
- •Receiving any other investigational agents which may affect patient's lymphocyte counts. Note: There is no evidence that chloroquine or hydroxychloroquine could affect lymphocyte counts. Thus, chloroquine or hydroxychloroquine use is not an exclusion criteria for this study. Additionally, it is permissible for potential participants to have received investigational or off-label agents for COVID-19 prior to or during study participation.
- •Pregnant or breastfeeding women are excluded from this study because NT-I7 has not been evaluated regarding its potential for teratogenic or abortifacients effects. There is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drug; therefore, breastfeeding should be discontinued if the mother is treated with NT-I
- •Transferred from ICU to the floor.
- •Requiring dialysis.
- •Shortness of breath or known hypoxia (defined as PaO2/FiO2 ≤ 300 mmHg), or signs of serious lower airway disease.
- •Evidence of ARDS, SIRS/shock, or cardiac failure.
- •Elevated inflammatory markers such as CRP > 2 x ULN, LDH > 2 x ULN, D-dimer > 2 x ULN, ferritin > ULN, or IL-6 > ULN (when available).
- •Any established diagnosis of autoimmune disease requiring systemic treatment EXCEPT for vitiligo or endocrine disease (such as diabetes, thyroid disease, and adrenal disease) controlled by replacement therapy.
- •Receipt of live attenuated vaccine within 30 days before the study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), Zoster, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed.
研究组 & 干预措施
NT-I7 (Phase I)
Experimental
- In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant
- NT-I7 will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: NT-I7 (Drug)
NT-I7 (Phase I)
Experimental
- In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant
- NT-I7 will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Blood for research purposes (Procedure)
NT-I7 (Phase I)
Experimental
- In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant
- NT-I7 will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Blood for pharmacokinetic samples (Procedure)
NT-I7 (Phase I)
Experimental
- In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant
- NT-I7 will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Nasopharyngeal, oropharyngeal, or saliva swab (Procedure)
Placebo (Pilot)
Placebo Comparator
- Placebo will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Blood for anti-drug antibody (ADA) (Procedure)
NT-I7 (Phase I)
Experimental
- In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant
- NT-I7 will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Blood for anti-drug antibody (ADA) (Procedure)
NT-I7 (Pilot)
Experimental
- NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: NT-I7 (Drug)
NT-I7 (Pilot)
Experimental
- NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Blood for research purposes (Procedure)
NT-I7 (Pilot)
Experimental
- NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Nasopharyngeal, oropharyngeal, or saliva swab (Procedure)
NT-I7 (Pilot)
Experimental
- NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Blood for anti-drug antibody (ADA) (Procedure)
Placebo (Pilot)
Placebo Comparator
- Placebo will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Placebo (Drug)
Placebo (Pilot)
Placebo Comparator
- Placebo will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Blood for research purposes (Procedure)
Placebo (Pilot)
Placebo Comparator
- Placebo will be given by intramuscular injection on Day 0
- Participants will also be given standard of care treatment for COVID-19
干预措施: Nasopharyngeal, oropharyngeal, or saliva swab (Procedure)
结局指标
主要结局
Safe and tolerable dose of NT-I7 (Phase I only)
时间窗: Completion of DLT assessment window of Phase I portion of study (estimated to be 8 months)
* The safe tolerated dose is defined as the dose level immediately below the dose level at which 1 patient of a cohort of 3 patients experiences dose-limiting toxicity within 14 days after administration of NT-I7 * Dose limiting toxicities (DLT) are defined as: * A serious adverse event that is at least possibly related to NT-I7 * A grade 3 or higher adverse event that is at least possibly related to NT-I7 (excluding injection site swelling, irritation or discomfort) * A clinically significant lab abnormality that is at least possibly related to NT-I7
Percent change in absolute lymphocyte count (ALC)
时间窗: From baseline to Day 14
次要结局
- Change in SARS-CoV-2 viral load(From baseline to Day 14)
- Percent change in absolute lymphocyte count (ALC)(From baseline through Day 21)
- COVID-19 Symptom severity as measured by WHO Ordinal Scale for clinical improvement(From baseline, day 7, day 14, and day 21)
- Incidence of treatment-emergent adverse events(From baseline through Day 21)
- Time to resolution of COVID-19 symptoms(From baseline through Day 21)
- Number of participants by PCR result status (positive or negative)(From baseline to Day 14)
研究者
相似试验
已完成
不适用
COVID-19 Associated Lymphopenia Pathogenesis Study in BloodCoronavirus Disease 2019NCT04401436National Institute of Allergy and Infectious Diseases (NIAID)240
已完成
不适用
Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19Covid19Older PeopleLymphopeniaNCT04800731Universitair Ziekenhuis Brussel227
已完成
不适用
Etiology of Lymphopenia in Covid19 InfectionLymphopeniaNCT04404608Dr Medhat Khafagy172
终止
2 期
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19Covid19HypoxemiaNCT04771000Noorik Biopharmaceuticals AG88
已完成
2 期
A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)Covid19NCT04481685University of Kansas Medical Center20